BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pierantozzi M, Pietroiusti A, Sancesario G, Lunardi G, Fedele E, Giacomini P, Frasca S, Galante A, Marciani MG, Stanzione P. Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson’s disease patients. Neurol Sci. 2001;22:89-91. [PMID: 11487216 DOI: 10.1007/s100720170061] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Lubomski M, Tan AH, Lim SY, Holmes AJ, Davis RL, Sue CM. Parkinson's disease and the gastrointestinal microbiome. J Neurol 2020;267:2507-23. [PMID: 31041582 DOI: 10.1007/s00415-019-09320-1] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 21.5] [Reference Citation Analysis]
2 Nyholm D, Hellström PM. Effects of Helicobacter pylori on Levodopa Pharmacokinetics. J Parkinsons Dis 2021;11:61-9. [PMID: 33164946 DOI: 10.3233/JPD-202298] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
3 Rajput C, Sarkar A, Sachan N, Rawat N, Singh MP. Is Gut Dysbiosis an Epicenter of Parkinson's Disease? Neurochem Res 2021;46:425-38. [PMID: 33400024 DOI: 10.1007/s11064-020-03187-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Fang X. Microbial treatment: the potential application for Parkinson's disease. Neurol Sci 2019;40:51-8. [PMID: 30415447 DOI: 10.1007/s10072-018-3641-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
5 Hatton GB, Madla CM, Rabbie SC, Basit AW. Gut reaction: impact of systemic diseases on gastrointestinal physiology and drug absorption. Drug Discov Today 2019;24:417-27. [PMID: 30453059 DOI: 10.1016/j.drudis.2018.11.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
6 Niehues M, Hensel A. In-vitro interaction of l -dopa with bacterial adhesins of Helicobacter pylori: an explanation for clinicial differences in bioavailability? Journal of Pharmacy and Pharmacology 2009;61:1303-7. [DOI: 10.1211/jpp.61.10.0005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
7 Rees K, Stowe R, Patel S, Ives N, Breen K, Clarke CE, Ben-Shlomo Y. Helicobacter pylori eradication for Parkinson's disease. Cochrane Database Syst Rev 2011;:CD008453. [PMID: 22071847 DOI: 10.1002/14651858.CD008453.pub2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
8 Heetun ZS, Quigley EM. Gastroparesis and Parkinson's disease: a systematic review. Parkinsonism Relat Disord 2012;18:433-40. [PMID: 22209346 DOI: 10.1016/j.parkreldis.2011.12.004] [Cited by in Crossref: 97] [Cited by in F6Publishing: 72] [Article Influence: 9.7] [Reference Citation Analysis]
9 Dardiotis E, Tsouris Z, Mentis AA, Siokas V, Michalopoulou A, Sokratous M, Dastamani M, Bogdanos DP, Deretzi G, Kountouras J. H. pylori and Parkinson's disease: Meta-analyses including clinical severity. Clin Neurol Neurosurg. 2018;175:16-24. [PMID: 30308319 DOI: 10.1016/j.clineuro.2018.09.039] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 13.7] [Reference Citation Analysis]
10 Lee WY, Yoon WT, Shin HY, Jeon SH, Rhee P. Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease. Mov Disord 2008;23:1696-700. [DOI: 10.1002/mds.22190] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 4.2] [Reference Citation Analysis]
11 Alvarez-Arellano L, Maldonado-Bernal C. Helicobacter pylori and neurological diseases: Married by the laws of inflammation. World J Gastrointest Pathophysiol. 2014;5:400-404. [PMID: 25400983 DOI: 10.4291/wjgp.v5.i4.400] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 35] [Article Influence: 6.1] [Reference Citation Analysis]
12 Pan JX, Deng FL, Zeng BH, Zheng P, Liang WW, Yin BM, Wu J, Dong MX, Luo YY, Wang HY, Wei H, Xie P. Absence of gut microbiota during early life affects anxiolytic Behaviors and monoamine neurotransmitters system in the hippocampal of mice. J Neurol Sci 2019;400:160-8. [PMID: 30954660 DOI: 10.1016/j.jns.2019.03.027] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
13 Maeda T, Nagata K, Satoh Y, Yamazaki T, Takano D. High prevalence of gastroesophageal reflux disease in Parkinson's disease: a questionnaire-based study. Parkinsons Dis 2013;2013:742128. [PMID: 23476890 DOI: 10.1155/2013/742128] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
14 Çamcı G, Oğuz S. Association between Parkinson's Disease and Helicobacter Pylori. J Clin Neurol 2016;12:147-50. [PMID: 26932258 DOI: 10.3988/jcn.2016.12.2.147] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 9.6] [Reference Citation Analysis]
15 Klingelhoefer L, Reichmann H, Korczyn AD, Reichmann H, Chaudhuri KR. Parkinson’s Disease and Gastrointestinal Non Motor Symptoms: Diagnostic and Therapeutic Options – A Practise Guide. JPD 2015;5:647-58. [DOI: 10.3233/jpd-150574] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Stillhart C, Vučićević K, Augustijns P, Basit AW, Batchelor H, Flanagan TR, Gesquiere I, Greupink R, Keszthelyi D, Koskinen M, Madla CM, Matthys C, Miljuš G, Mooij MG, Parrott N, Ungell A, de Wildt SN, Orlu M, Klein S, Müllertz A. Impact of gastrointestinal physiology on drug absorption in special populations––An UNGAP review. European Journal of Pharmaceutical Sciences 2020;147:105280. [DOI: 10.1016/j.ejps.2020.105280] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 37.0] [Reference Citation Analysis]
17 Hatton GB, Madla CM, Rabbie SC, Basit AW. All disease begins in the gut: Influence of gastrointestinal disorders and surgery on oral drug performance. Int J Pharm 2018;548:408-22. [PMID: 29969711 DOI: 10.1016/j.ijpharm.2018.06.054] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 10.0] [Reference Citation Analysis]
18 Moustafa SA, Mohamed S, Dawood A, Azar J, Elmorsy E, Rizk NAM, Salama M. Gut brain axis: an insight into microbiota role in Parkinson's disease. Metab Brain Dis 2021. [PMID: 34370175 DOI: 10.1007/s11011-021-00808-2] [Reference Citation Analysis]
19 Lorente-Picón M, Laguna A. New Avenues for Parkinson's Disease Therapeutics: Disease-Modifying Strategies Based on the Gut Microbiota. Biomolecules 2021;11:433. [PMID: 33804226 DOI: 10.3390/biom11030433] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
20 Zendehdel A, Roham M. Biological evidence of the relationship between Helicobacter pylori and associated extragastric diseases. J Cell Biochem 2019;120:12128-40. [DOI: 10.1002/jcb.28681] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
21 Bu X, Wang X, Xiang Y, Shen L, Wang Q, Liu Y, Jiao S, Wang Y, Cao H, Yi X, Liu C, Deng B, Yao X, Xu Z, Zhou H, Wang Y. The association between infectious burden and Parkinson's disease: A case-control study. Parkinsonism & Related Disorders 2015;21:877-81. [DOI: 10.1016/j.parkreldis.2015.05.015] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 11.0] [Reference Citation Analysis]
22 Zhang X, Han Y, Huang W, Jin M, Gao Z. The influence of the gut microbiota on the bioavailability of oral drugs. Acta Pharm Sin B 2021;11:1789-812. [PMID: 34386321 DOI: 10.1016/j.apsb.2020.09.013] [Reference Citation Analysis]
23 Lahner E, Annibale B, Delle Fave G. Systematic review: Helicobacter pylori infection and impaired drug absorption. Aliment Pharmacol Ther. 2009;29:379-386. [PMID: 19053985 DOI: 10.1111/j.1365-2036.2008.03906.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
24 Ilie OD, Ciobica A, McKenna J, Doroftei B, Mavroudis I. Minireview on the Relations between Gut Microflora and Parkinson's Disease: Further Biochemical (Oxidative Stress), Inflammatory, and Neurological Particularities. Oxid Med Cell Longev 2020;2020:4518023. [PMID: 32089768 DOI: 10.1155/2020/4518023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
25 Müller T, Möhr J. Long-term management of Parkinson’s disease using levodopa combinations. Expert Opinion on Pharmacotherapy 2018;19:1003-11. [DOI: 10.1080/14656566.2018.1484108] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
26 Quigley EMM. Microbiota-Brain-Gut Axis and Neurodegenerative Diseases. Curr Neurol Neurosci Rep 2017;17:94. [PMID: 29039142 DOI: 10.1007/s11910-017-0802-6] [Cited by in Crossref: 205] [Cited by in F6Publishing: 158] [Article Influence: 51.3] [Reference Citation Analysis]
27 Collins SL, Patterson AD. The gut microbiome: an orchestrator of xenobiotic metabolism. Acta Pharm Sin B 2020;10:19-32. [PMID: 31998605 DOI: 10.1016/j.apsb.2019.12.001] [Cited by in Crossref: 39] [Cited by in F6Publishing: 27] [Article Influence: 19.5] [Reference Citation Analysis]
28 Parashar A, Udayabanu M. Gut microbiota: Implications in Parkinson's disease. Parkinsonism Relat Disord 2017;38:1-7. [PMID: 28202372 DOI: 10.1016/j.parkreldis.2017.02.002] [Cited by in Crossref: 102] [Cited by in F6Publishing: 78] [Article Influence: 25.5] [Reference Citation Analysis]
29 Shen X, Yang H, Wu Y, Zhang D, Jiang H. Meta-analysis: Association of Helicobacter pylori infection with Parkinson's diseases. Helicobacter 2017;22:e12398. [DOI: 10.1111/hel.12398] [Cited by in Crossref: 42] [Cited by in F6Publishing: 29] [Article Influence: 10.5] [Reference Citation Analysis]
30 Patrick KL, Bell SL, Weindel CG, Watson RO. Exploring the "Multiple-Hit Hypothesis" of Neurodegenerative Disease: Bacterial Infection Comes Up to Bat. Front Cell Infect Microbiol 2019;9:138. [PMID: 31192157 DOI: 10.3389/fcimb.2019.00138] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 13.0] [Reference Citation Analysis]
31 Lahner E, Virili C, Santaguida MG, Annibale B, Centanni M. Helicobacter pylori infection and drugs malabsorption. World J Gastroenterol. 2014;20:10331-10337. [PMID: 25132749 DOI: 10.3748/wjg.v20.i30.10331] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
32 Sun CY, Li JR, Wang YY, Lin SY, Ou YC, Lin CJ, Wang JD, Liao SL, Chen CJ. Indoxyl sulfate caused behavioral abnormality and neurodegeneration in mice with unilateral nephrectomy. Aging (Albany NY) 2021;13:6681-701. [PMID: 33621199 DOI: 10.18632/aging.202523] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
33 Gazerani P. Probiotics for Parkinson's Disease. Int J Mol Sci 2019;20:E4121. [PMID: 31450864 DOI: 10.3390/ijms20174121] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 16.5] [Reference Citation Analysis]
34 Munoz-Pinto MF, Empadinhas N, Cardoso SM. The neuromicrobiology of Parkinson's disease: A unifying theory. Ageing Res Rev 2021;70:101396. [PMID: 34171417 DOI: 10.1016/j.arr.2021.101396] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Fried S, Wemelle E, Cani PD, Knauf C. Interactions between the microbiota and enteric nervous system during gut-brain disorders. Neuropharmacology 2021;197:108721. [PMID: 34274348 DOI: 10.1016/j.neuropharm.2021.108721] [Reference Citation Analysis]